Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
IDO1
Name:
indoleamine 23-dioxygenase 1
Location:
08p11.21
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT02764151 | First in Patient Study for PF-06840003 in Malignant Gliomas | View | |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable Recurrent or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | View | |
| NCT02559492 | Itacitinib Combined With INCB024360 andor Itacitinib Combined With INCB050465 in Advanced Solid Tumors | View | |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | View | |
| NCT01604889 | A Phase 12 Randomized Blinded Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | View | |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer KEYNOTE-654-05ECHO-305-05 | View | |
| NCT03322566 | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer KEYNOTE-715-06ECHO-306-06 | View | |
| NCT02048709 | Indoleamine 23-Dioxygenase IDO Inhibitor in Advanced Solid Tumors | View | |
| NCT03459222 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | View | |
| NCT03260894 | Pembrolizumab MK-3475 Plus Epacadostat vs Standard of Care in mRCC KEYNOTE-679ECHO-302 | View | |
| NCT03414229 | A Study of Epacadostat an IDO1 Inhibitor in Combination With Pembrolizumab in Patients With Metastatic andor Locally Advanced Sarcoma | View | |
| NCT03491631 | Phase I Study of SHR9146 SHR-1210 - Apatinib in Patients With Advanced Solid Tumors | View | |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | View | |
| NCT03164603 | NLG802 Indoleamine 23-Dioxygenase IDO Inhibitor in Advanced Solid Tumors | View | |
| NCT03358472 | Pembrolizumab Plus Epacadostat Pembrolizumab Monotherapy and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma KEYNOTE-669ECHO-304 | View | |
| NCT03516708 | Epacadostat INCB024360 Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | View | |
| NCT03641794 | Indoleamine 23-Dioxygenase IDO Inhibitor in Healthy Volunteers | View | |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | View | |
| NCT05469490 | Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy SBRT Treatment of Advanced Solid Tumors | View | |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer Who Are in Remission | View | |
| NCT03896113 | Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma | View | |
| NCT02166905 | DEC-205NY-ESO-1 Fusion Protein CDX-1401 Poly ICLC and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian Fallopian Tube or Primary Peritoneal Cancer in Remission | View | |
| NCT03208959 | A Trial of HTI-1090 in Subjects With Advanced Solid Tumors | View | |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | View | |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | View | |
| NCT04047706 | Nivolumab BMS-986205 and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | View |